Article
Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation
| Author/s | Rey, E.
Ampuero Herrojo, Javier 
Molina-Jiménez, F. García-García, Y. Muñoz Hernández, Rocío
Romero Gómez, Manuel
García-Monzón, C. Majano, P. González-Rodríguez, A. |
| Department | Universidad de Sevilla. Departamento de Medicina |
| Date | 2021-01-12 |
| Published in |
|
| Abstract | In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first
time, revealed which molecular mechanisms are ... |
| Funding agencies | Instituto de Salud Carlos III European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) |
| Project ID. | PI16/00823
PI17/0535
PI17/0008 |
| Citation | Rey, E., Ampuero Herrojo, J., Molina-Jiménez, F., García-García, Y., Muñoz Hernández, R., Romero Gómez, M.,...,González-Rodríguez, A. (2021). Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clinical and translational medicine, 11 (1), e275. https://doi.org/10.1002/ctm2.275. |
: 
| Files | Size | Format | View | Description |
|---|---|---|---|---|
| Sofosbuvir...pdf | 1.688Mb | 
[PDF]
| View/ | |
https://hdl.handle.net/11441/139181
https://doi.org/10.1002/ctm2.275This item appears in the following collection(s)
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional